Clinical Trials Browser

Phase 2 × Anemia, Refractory, with Excess of Blasts × Hematopoietic Stem Cell Transplantation × Clear all

NCT07249346 2025-12-24

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Phase 2 Recruiting

124 enrolled

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myelomonocytic, Chronic

NCT03314974 2025-06-24

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Phase 2 Recruiting

300 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Leukemia, Plasma Cell, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis